Enzyme replacement therapy for infantile-onset Pompe disease.

Authors:
Min Chen
Min Chen
Peking University First Hospital
China
Lingli Zhang
Lingli Zhang
Central South University
China
Shuyan Quan
Shuyan Quan
West China Second University Hospital

Cochrane Database Syst Rev 2017 11 20;11:CD011539. Epub 2017 Nov 20.

Department of Pharmacy, West China Second University Hospital, Sichuan University, No. 20, Section 4, Renmin South Road, Chengdu, China, 610041.

Background: Infantile-onset Pompe disease is a rare and progressive autosomal-recessive disorder caused by a deficiency of the lysosomal enzyme acid alpha-glucosidase (GAA). Current treatment involves enzyme replacement therapy (with recombinant human alglucosidase alfa) and symptomatic therapies (e.g. to control secretions). Children who are cross-reactive immunological material (CRIM)-negative require immunomodulation prior to commencing enzyme replacement therapy.Enzyme replacement therapy was developed as the most promising therapeutic approach for Pompe disease; however, the evidence is lacking, especially regarding the optimal dose and dose frequency.

Objectives: To assess the effectiveness, safety and appropriate dose regimen of enzyme replacement therapy for treating infantile-onset Pompe disease.

Search Methods: We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group's Inborn Errors of Metabolism Trials Register, which is compiled from electronic database searches and handsearching of journals and conference abstract books. We also searched the Cochrane Central Register of Controlled Trials (CENTRAL), Embase (Ovid), PubMed and LILACS, and CBM, CNKI, VIP, and WANFANG for literature published in Chinese. In addition, we searched three online registers: WHO International Clinical Trials Registry Platform ClinicalTrials.gov, and www.genzymeclinicalresearch.com. We also searched the reference lists of relevant articles and reviews.Date of last search of the Group's Inborn Errors of Metabolism Trials Register: 24 November 2016.

Selection Criteria: Randomized and quasi-randomized controlled trials of enzyme replacement therapy in children with infantile-onset Pompe disease.

Data Collection And Analysis: Two authors independently selected relevant trials, assessed the risk of bias and extracted data. We contacted investigators to obtain important missing information.

Main Results: We found no trials comparing the effectiveness and safety of enzyme replacement therapy to another intervention, no intervention or placebo.We found one trial (18 participants) that fulfilled the selection criteria, comparing different doses of alglucosidase alfa. The trial provided low-quality evidence (this was a small trial, there were no numerical results available by dose group, random sequence generation and allocation concealment were unclear, and there was a lack of blinding). The duration of alglucosidase alfa treatment ranged from 52 weeks (the length of the original study) to up to three years (including the extended phase of the trial), with a median duration of treatment being 2.3 years.The trial only reported that clinical responses including cardiac function and motor development, as well as the proportion of children that were free of invasive ventilation, were similar in the 20 mg/kg every two weeks and the 40 mg/kg every two weeks groups (low-quality evidence). Long-term alglucosidase alfa treatment markedly extended survival as well as ventilation-free survival and improved cardiomyopathy (low-quality evidence). In relation to the number of children experiencing one or more infusion-related events, there was no significant difference between dose groups, risk ratio 0.83 (95% confidence interval 0.40 to 1.76) (low-quality of evidence). However, of note, at 52 weeks, five children in the 20 mg/kg every two weeks dose group experienced a total of 41 mild or moderate (none severe) infusion-related events and the six children in the 40 mg/kg every two weeks dose group experienced a total of 123 infusion-related events. By the end of the extended phase of the trial, five children in the 20 mg/kg every two weeks dose group experienced a total of 47 infusion-related events and the six children in the 40 mg/kg every two weeks dose group experienced a total of 177 infusion-related events. The trial was supported by the Genzyme Corporation.

Authors' Conclusions: The search found no trials comparing the effectiveness and safety of enzyme replacement therapy to another intervention, no intervention or placebo. One small randomized controlled trial provided no robust evidence for which dosing schedule of alglucosidase alfa was more effective to treat infantile-onset Pompe disease. It is not deemed ethical to proceed with new placebo-controlled trials, therefore a randomized controlled trial with a large sample size comparing different dosing schedules of enzyme replacement therapy is needed. The main clinical outcomes (i.e. cardiac function, invasive ventilation, survival, motor development, adverse events (e.g. the development of antibodies)) should be standardized when evaluated and reported.

Download full-text PDF

Source
http://dx.doi.org/10.1002/14651858.CD011539.pub2DOI Listing

Still can't find the full text of the article?

Sign up to send a request to the authors directly.
November 2017
8 Reads

Publication Analysis

Top Keywords

enzyme replacement
32
replacement therapy
32
mg/kg weeks
24
dose group
20
alglucosidase alfa
20
infusion-related events
20
infantile-onset pompe
20
low-quality evidence
16
pompe disease
16
weeks dose
16
children mg/kg
16
group experienced
16
experienced total
16
effectiveness safety
12
trial
9
trials
9
enzyme
9
dose
9
replacement
8
intervention intervention
8

References

(Supplied by CrossRef)
Enzyme replacement therapy (ERT) with recombinant human acid alpha glucosidase (rhGAA) in infantile onset Pompe disease (IOPD)
Kishnani et al.
Journal of Inherited Metabolic Disease 2005
Enzyme replacement therapy with recombinant human acid alpha glucosidase (rhGAA) in infantile onset Pompe disease (IOPD)
Kishnani et al.
Neuromuscular Disorders : NMD 2005
Treatment of infantile Pompe disease with alglucosidase alpha: the UK experience
Chakrapani et al.
Journal of Inherited Metabolic Disease 2010
Safety and efficacy results from a randomized, double-blind, placebo-controlled study of alglucosidase alpha for the treatment of Pompe's disease in juveniles and adults
Ploeg et al.
European Journal of Neurology 2008

Similar Publications

Evaluation of the implementation of single screening and treatment for the control of malaria in pregnancy in Eastern Indonesia: a systems effectiveness analysis.

Malar J 2018 Aug 24;17(1):310. Epub 2018 Aug 24.

Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK.

Background: Indonesia introduced single screening and treatment (SST) of pregnant women for the control of malaria in pregnancy in 2012. Under this policy pregnant women are screened for malaria at their first antenatal clinic (ANC) visit and on subsequent visits are tested for malaria only if symptomatic. The implementation of this policy in two districts of Indonesia was evaluated. Read More

View Article
August 2018
8 Reads
3.11 Impact Factor

The Relationship of 5-Aminolevulinic Acid on Mood and Coping Ability in Prediabetic Middle Aged and Older Adults.

Geriatrics (Basel) 2018 Jun 4;3(2). Epub 2018 Apr 4.

Department of Geriatrics and Department of Complementary and Alternative Medicine, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI 96813, USA.

In 2010, approximately 79 million Americans had prediabetes and about 50 percent of those individuals were 65 years and older. The most effective diabetes prevention method in prediabetic adults is lifestyle modification. However, despite the benefits of lifestyle change, diabetes prevalence continues to increase. Read More

View Article
June 2018
37 Reads

Protective effect of captopril against diazinon induced nephrotoxicity and neurotoxicity via inhibition of ROS-NO pathway.

Drug Chem Toxicol 2018 Jul 8;41(3):287-293. Epub 2017 Nov 8.

b Department of Toxicology and Pharmacology, Faculty of Pharmacy , Mazandaran University of Medical Sciences , Sari , Iran.

Diazinon (Dz) is a widely used insecticide. It can induce nephrotoxicity and neurotoxicity via oxidative stress. Captopril, an angiotensin-converting enzyme inhibitor, is known for its antioxidant properties. Read More

View Article
July 2018
9 Reads
1.10 Impact Factor

Screening of natural yeast isolates under the effects of stresses associated with second-generation biofuel production.

J Biosci Bioeng 2016 May 21;121(5):509-16. Epub 2015 Oct 21.

Synthetic Biology and Biofuels Group, International Centre for Genetic Engineering and Biotechnology, Aruna Asaf Ali Marg, New Delhi 110067, India. Electronic address:

Robust microorganisms are required for sustainable second-generation biofuel production. We evaluated the growth and fermentation performance of six natural isolates that were derived from grape wine and medicinal herbs using a wide range of carbon sources, rice and wheat straw hydrolysates as well as stress conditions associated with second-generation ethanol production. Sequence analysis of the 5. Read More

View Article
May 2016
2 Reads

Metabolic vs. hedonic obesity: a conceptual distinction and its clinical implications.

Obes Rev 2015 Mar 14;16(3):234-47. Epub 2015 Jan 14.

Weight Loss and Diabetes Center, Greenwich Hospital, Greenwich, CT, USA; Endocrinology Associates of Greenwich, Northeast Medical Group, Yale New-Haven Health System, Greenwich, CT, USA.

Body weight is determined via both metabolic and hedonic mechanisms. Metabolic regulation of body weight centres around the 'body weight set point', which is programmed by energy balance circuitry in the hypothalamus and other specific brain regions. The metabolic body weight set point has a genetic basis, but exposure to an obesogenic environment may elicit allostatic responses and upward drift of the set point, leading to a higher maintained body weight. Read More

View Article
March 2015
3 Reads
11 PubMed Central Citations(source)
8.00 Impact Factor